CMO Kemwell is receiving technical assistance from Boehringer Ingelheim for the construction of its new biotech facility, which is designed to marry European technology with Indian low cost manufacturing.
Boehringer Ingelheim has been forced to announce the planned
closure of a UK manufacturing site as a result of pricing pressures
that mean the firm is unable to produce unit dose vials (UDVs) at
the site cost-effectively.
The world's most prescribed product for chronic obstructive
pulmonary disease (COPD) could soon be formulated with a new
propellant-free device following an observational study on a soft
mist inhaler (SMI) that Boehringer Ingelheim...
Jacobs Engineering Group has inked a new contract with Boehringer
Ingelheim to provide technical and construction services for its
new bulk active pharmaceutical ingredient (API) facility being
built in Petersburg, Virginia, US.
British drug delivery firm Vectura has inked a deal with Boehringer
Ingelheim to develop a dry powder inhaler (DPI) for a range of
proprietary respiratory products of the German company,
intensifying competition in a burgeoning asthma...
Oracle has introduced a new software program to help pharma
companies integrate clinical data from multiple sources and
streamline regulatory compliance in the clinical development
process. Pharma giant Boehringer Ingelheim is the...
The interest in Syntonix' SynFusion and Transceptor technologies
intensified as Boehringer Ingelheim became the second
pharmaceutical company to use this technology to optimise its
therapeutic peptides for inhalation.
The chemicals subsidiary of Germany's Boehringer Ingelheim is
expanding its manufacturing capacity for the nasal decongestant
phenylephrine hydrochloride to tap into what it said is growing
German pharmaceutical company, Boehringer Ingelheim (BI) and Ark
Therapeutics have signed an agreement granting BI exclusive rights
to Ark's intellectual property in relation to BI therapies
affecting the renin-angiotensin system.
German biotech company Evotec OAI posted decreased third quarterly
revenues of €16.1 million, down 26 per cent compared to 2003.
Evotec's performance reflects the difficult operating environment
for companies supplying drug discovery...